StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $9.22 | $9.20 | -0.22% | 1.1M |
| 05-19 | $9.21 | $8.96 | -2.71% | 1.4M |
| 05-20 | $8.98 | $10.34 | +15.14% | 5.3M |
| 05-21 | $10.20 | $11.13 | +9.12% | 5.2M |
| 05-22 | $11.12 | $11.25 | +1.17% | 2.5M |
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $18.27M | $67.48M | $50.15M | $29.40M |
Operating Income | $-78.81M | $-303.63M | $-217.36M | $-137.37M |
Net Income | $-73.33M | $-278.67M | $-197.67M | $-66.12M |
EPS (Diluted) | $-0.83 | $-3.18 | $-2.26 | $-1.41 |
Total Assets | $652.55M | $738.36M | $649.38M | $682.42M |
Total Liabilities | $544.67M | $564.23M | $406.84M | $376.94M |
Cash & Equivalents | $39.08M | $149.10M | $95.29M | $81.95M |
Free Cash Flow OCF − CapEx | $-85.98M | $-70.70M | $-185.65M | $-102.45M |
Shares Outstanding | 88.76M | 87.86M | 87.02M | 86.80M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.